Novartis

Phone: +355 4 223 2444

Fax: +355 4 223 0843

Web: https://www.novartis.com

Type	Public (Aktiengesellschaft)
Traded as	SIX: NOVN NYSE: NVS
ISIN
Industry	Pharmaceuticals
Predecessors	Ciba-Geigy Sandoz (via merger)
Founded	March 1996 (1996-03) (from merger)
Founders	Johann Rudolf Alexander Clavel
Headquarters	Basel, Switzerland Cambridge, Massachusetts, United States (global research)
Area served	Worldwide
Key people	Vasant Narasimhan (CEO)
Products	Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health (list...)
Revenue	US$51.63 billion (2021)
Operating income	US$11.69 billion (2021)
Net income	US$24.02 billion (2021)
Total assets	US$131.79 billion (2021)
Total equity	US$67.82 billion (2021)
Number of employees	110,000 (2021)
Website	www.novartis.com

Novartis is structured to deliver innovative products, exploit global scale, and respond to new opportunities and risks. Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.

For detailed contact information visit location pages below.